VEGF expression and response to sunitinib in patients with metastatic clear cell renal cell carcinoma

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 5017-5022

  Minardi, Daniele ^a   Lucarini, Guendalina ^a   Santoni, Matteo ^a   Mazzucchelli, Roberta ^a   Burattini, Luciano ^a   Pistelli, Mirco ^a   Bianconi, Maristella ^a   Di Primio, Roberto ^a   Scartozzi, Mario ^a   Montironi, Rodolfo ^a   Cascinu, Stefano ^a   Muzzonigro, Giovanni ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Distant metastasis free survival; Overall survival; Renal cell carcinoma; Vascular endothelial growth factor

Indexed keywords

BIOLOGICAL MARKER; SUNITINIB; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MALE; MEMORIAL SLOAN KETTERING CANCER CENTER SCORE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADICAL RESECTION; SCORING SYSTEM; TREATMENT RESPONSE;

DISTANT METASTASIS-FREE SURVIVAL; OVERALL SURVIVAL; RENAL CELL CARCINOMA; VASCULAR ENDOTHELIAL GROWTH FACTOR;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PYRROLES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84891348461     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kamangar F, Dores GM and Anderson WF: Patterns of incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-215, 2006.
2. Choueiri TK, Garcia JA, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI and Bukowski RM: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110: 543-550, 2007.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
4. Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30: 843-852, 2003.
5. Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC and Rha SY: Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single center cancer experience in Korea. Cancer Res Treat 41: 67-72, 2009.
6. Herrmann E, Bierer S and Wülfing C: Update on systemic therapies of metastatic renal cell carcinoma: World J Urol 28: 303-309, 2010.
7. Rini BI, Rathmell WK and Godley P: Renal cell carcinoma. Curr Opin Oncol 20: 300-316, 2008.
8. Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S and Mazumdar M: Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22: 454-632, 2004.
9. Motzer RJ, Bacik J, Murphy BA, Russo P and Mazumdar M: Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20: 289-296, 2005.
10. Miyake H, Kurahashi T, Takenaka A, Inoue TA and Fujisawa M: Clinical outcome of combined immunotherapy with interferon-α and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 27: 598-603, 2009.
11. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM, Lubensky I, Duan DR, Florence C, Pozzatti R, Walther M M, Bander NH, Grossman HB, Brauch H, Pomer S, Brooks JD, Isaacs WB, Lerman MI, Zbar B and Linehanet WM: Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Gene 7: 85-90, 1994.
12. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L, Schmidt L, Zhou F, Li H, Wei MH, Chen F, Glenn G, Choyke P, Walther McMM, Weng Y, Duan DSR, Dean M, Glavac D, Richards FM, Crossey PA, Fergurson-Smith MA, Le Paslier D, Chumakov I, Cohen D, Chinault AC, Maher ER, Linehan WM, Zbar B and Lerman MI: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 260: 1317-1320, 1993.
13. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S and Sukhatme VP: The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17: 5629-5639, 1997.
14. Xu L, Tong R, Cochran DM and Jain RK: Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor β signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res 65: 5711-5719, 2005.
15. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Buckowski RM: Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med 356: 125-134, 2007.
16. Motzer RJ, Jutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM and Figlin RA: Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 356: 115-124, 2007.
17. Algaba F, Azaka H, López-Beltrán A, Martignoni G, Moch H, Montironi R and Reuter V: Current pathology keys of renal carcinoma. Eur Urol 60: 634-643, 2011.
18. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A and Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540, 1999.
19. Detre S, Saccani Jotti G and Dowsett M: A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48: 876-878, 1995.
20. Kaplan E and Meier P: Non parametric estimation for incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
21. Rini BI and Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043, 2005.
22. Jacobsen J, Grankvist K, Rasmuson T, Bergh A, Landberg G and Ljungberg B: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93: 297-302, 2004.
23. Gan HK, Seruga B and Knox JJ: Sunitinib in solid tumors. Expert Opin Investig Drugs 18: 821-834, 2009.
24. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G and Cherrington JM: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337, 2003.
25. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X and Figlin RA: Overall survival and updated results for sunitinib compared with interferon á in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009.
26. Rini BI and Atkins MB: Resistance to targeted therapy in renal cell carcinoma. Lancet Oncol 10: 992-1000, 2009.
27. Sakai I, Miyake H and Fujisawa M: Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int 112: E211-E220, 2013.
28. Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Di Primio R, Montironi R and Muzzonigro G: Prognostic role of tumor necrosis, microvessel density (MVD), vascular endothelial growht factor (VEGF) and hypoxia inducile factor-1α (HIF-1α) in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up. Int J Immunopathol Pharmacol 21: 447-455, 2008.
29. Jubb AM, Hurwitz HI, Bai W, Holmgren EB, Tobin P, Guerrero AS, Kabbinavar F, Holden SN, Novotny WF, Frantz GD, Hillan KJ and Koeppen H: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24: 217-227, 2006.
30. Hegde PS, Jubb AM, Chen D, Li NF, Meng YG, Bernaards C, Elliott R, Scherer SJ and Chen DS: Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res 19: 929-937, 2013.
31. Porta C, Paglino C, De Amici M, Quaglini S, Sacchi L, Imarisio I and Canipari C: Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 77: 809-815, 2010.
32. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naïmi B, Porcher R, de La Taille A, Menashi S, Calvo F and Mourah S: Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS ONE 5: 1-5, 2010.
33. Schneider BP, Radovich M and Miller KD: The role of vascular endothelial growth factor variability in cancer. Clin Cancer Res 15: 5297-5530, 2009.
34. Schultheis AM, Lurje G, Rhodes KE, Zhang W, Yang D, Garcia AA, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L and Lenz HJ: Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14: 7554-7563, 2008.
35. Formica V, Palmirotta R, Del Monte G, Savonarola A, Ludovici G, De Marchis ML, Grenga I, Schirru M, Guadagni F and Roselli M: Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan and bevacizumab. Int J Colorectal Dis 26: 143-151, 2011.
36. Fojo T and Wilkerson J: Bevacizumab and breast cancer: The E2100 outlier. Lancet Oncol 11: 1117-1119, 2010.
37. Eng L, Azad AK, Habbous S, Pnag V, Xu W, van der Zee AHM, Savas S, Mackay H, Amir E and Liu G: Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: A systematic review and meta-analysis. Clin Cancer Res 18: 4526-4537, 2012.